CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $105.28M, above the global median of $16.24M
- FinancialsAltman Z-Score 0.39: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.35BCNY496.90M · vs all stocks (USD)
Revenue (TTM)
1.33BCNY197.23M · vs all stocks (USD)
Profit Margin
-34.86%Beta
0.2670xvs all stocks
52-Week Change
-20.95%vs all stocks
Market Capitalization
3.35BCNY496.90M · vs all stocks (USD)
Enterprise Value
4.21BCNY624.61M · vs all stocks (USD)
Forward P/E
56.40xPrice to Sales (TTM)
2.51xPrice to Book (MRQ)
3.91xEnterprise to Revenue
3.17xEnterprise to EBITDA
18.68xGross Margin
33.25%Profit Margin
-34.86%Operating Margin
10.26%Return on Assets (TTM)
2.43%Return on Equity (TTM)
-39.64%Revenue (TTM)
1.33BCNY197.23M · vs all stocks (USD)
Revenue per Share (TTM)
1.12CNYUpdated Aug 19, 2026Quarterly Revenue Growth
2.10%Gross Profit (TTM)
449.95MCNY66.83M · vs all stocks (USD)
EBITDA (TTM)
163.74MCNY24.32M · vs all stocks (USD)
Net Income (TTM)
-462.97MCNY-68.76M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-0.40%Operating Cash Flow (TTM)
307.83MCNY45.72M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
708.87MCNY105.28M · vs all stocks (USD)
5-Year Average Dividend Yield
0.45%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
71.17MCNYFY2025 · Dec 31, 2025Revenue
1.32BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
831.92MCNYFY2025 · Dec 31, 2025Gross Profit
489.54MCNYFY2025 · Dec 31, 2025Operating Income
167.91MCNY24.94M · vs all stocks (USD)
Pre-tax Income
-458.94MCNYFY2025 · Dec 31, 2025Income Tax Expense
447.76KCNYFY2025 · Dec 31, 2025Net Income
-459.39MCNYFY2025 · Dec 31, 2025EBIT
-416.97MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
277.61MCNYFY2025 · Dec 31, 2025Research & Development
67.83MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
47.15MCNYFY2025 · Dec 31, 2025Other Operating Expenses
22.25MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
523.30KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
41.97MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.3916CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.3916CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.18BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.18BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-459.39MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-3.51MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-318.11MCNYFY2025 · Dec 31, 2025Free Cash Flow
-367.07MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
95.35MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-459.39MCNYFY2025 · Dec 31, 2025Other Non-cash Items
50.19MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
51.63MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
39.46MCNYFY2025 · Dec 31, 2025Capital Expenditures
-48.96MCNYFY2025 · Dec 31, 2025Net Acquisitions
1.71MCNYFY2025 · Dec 31, 2025Sale of Investments
360.61KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-46.89MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
538.85MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-885.25MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-42.46MCNYFY2025 · Dec 31, 2025Other Financing Charges
-455.00KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-389.32MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.18BSharesUpdated Aug 19, 2026Float Shares
885.28MSharesUpdated Aug 19, 2026% Held by Insiders
39.47%vs all stocks
% Held by Institutions
0.91%vs all stocks
Total Cash (MRQ)
185.49MCNY27.55M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1570CNYUpdated Aug 19, 2026Total Debt (MRQ)
902.43MCNY134.03M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.9747xCurrent Ratio (MRQ)
0.8200xBook Value per Share (MRQ)
0.7220CNYUpdated Aug 19, 2026Total Assets
2.70BCNY401.30M · vs all stocks (USD)
Total Current Assets
993.88MCNYFY2025 · Dec 31, 2025Total Liabilities
1.79BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.71BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
318.41MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.47BCNYFY2025 · Dec 31, 2025Cash
138.96MCNYFY2025 · Dec 31, 2025Cash Equivalents
9.73KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
138.97MCNYFY2025 · Dec 31, 2025Accounts Receivable
484.14MCNYFY2025 · Dec 31, 2025Inventory
241.51MCNYFY2025 · Dec 31, 2025Accounts Payable
199.90MCNYFY2025 · Dec 31, 2025Short-term Debt
964.29MCNYFY2025 · Dec 31, 2025Other Current Liabilities
4.69MCNYFY2025 · Dec 31, 2025Long-term Debt
271.01MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.18BCNYFY2025 · Dec 31, 2025Retained Earnings
-962.90MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
909.06MCNY135.01M · vs all stocks (USD)
52-Week Low
2.41CNYUpdated Aug 19, 202652-Week High
3.66CNYUpdated Aug 19, 202652-Week Change
-20.95%vs all stocks
Beta
0.2670xvs all stocks
50-Day MA
2.69CNYUpdated Aug 19, 2026200-Day MA
3.09CNYUpdated Aug 19, 2026Avg 10-Day Volume
33.30MSharesUpdated Aug 19, 2026Avg 30-Day Volume
28.90MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-0.3900CNYUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 0.39: distress zoneCritical
Altman Z-Score: 0.39
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $105.28M, above the global median of $16.24MNotable
Levered free cash flow (USD): 105,281,403.292Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Succeeder Technology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hyundai Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai ZJ Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
OrthoPediatrics Corp.
Tier 1ProductionApproval-Gated PipelineRule
ProKidney Corp
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Shen Lian Bio-Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sd Biosensor Inc.
Tier 1ProductionApproval-Gated PipelineRule
G2GBio Inc.
Tier 1ProductionApproval-Gated PipelineRule
Daewoong Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pku Healthcare Corporation Limited
Tier 1ProductionApproval-Gated PipelineRule